Delcath Systems said Wednesday that its liver-tumor treatment device achieved the primary goal of a late-stage clinical trial, but questions about the strength of the data — and whether the results will satisfy regulators — caused the small company’s stock price to fall.

The Delcath device, called Hepzato, consists of clamps, tubes, and a filter that isolate a patient’s liver from the rest of the bloodstream. Once the liver is blocked off, it is bathed in high doses of the chemotherapy melphalan to kill tumors. The Hepzato filter removes the melphalan from the patient before it can escape the liver, enter the bloodstream, and cause severe side effects or death.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What’s included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.


Leave a Reply

ArabicChinese (Simplified)EnglishFrenchGermanItalianJapanesePortugueseRussianSpanish

[mc4wp_form id="449"]